4 / 30
Orthopedics and Osteoporosis 2018
N o v e m b e r 2 9 - 3 0 , 2 0 1 8
Am s t e r d a m , N e t h e r l a n d s
Page 22
Journal of Clinical & Experimental Orthopaedics
ISSN: 2471-8416
E u r o p e a n C o n f e r e n c e o n
Orthopedics and
Osteoporosis
LifeAid Combo is a composition of vitamins and CBD developed for a wide
array of autoimmune conditions, covering Guillain-Barré, multiple sclerosis,
rheumatoid arthritis, Crohn, asthma, vasculitis and fibromyalgia. LifeAid
Combo is a patient based initiative, created by a patient and tested by the
patients via testimonials in the initial trial, advised by the expertise of Baruch
Styr, pharmacist, Batya Kornboim, MD, and Igal Yusim research.
Methodology:
All trial participants have consulted with their personal
physicians was informed of the risks and is volunteered. After a thorough
screening process, 112 volunteers qualified for the trial in the rheumatoid
arthritis group. 107 participants completed the trial. No deaths or medical
emergencies were found on follow up; all dropouts didn’t keep up with the
regimen for personal reasons. The participants were given a self-report
questionnaire to fill out once a day regarding the effects of the LifeAid combo
for 100 days over five life aspects: appetite, fatigue, movement, pain, sleep.
Effectiveness of the treatment was assessed through simple line regression,
over 20% is considered to be effective and less than 20% was considered to be
not-effective.
Appetite
52%
Fatigue
39%
Movement
53%
Pain
72%
Sleep
27%
Table 1:
Results:
Initial trial results have shown the treatment to have the greatest
effect on appetite, movement and pain for the rheumatoid arthritis group.
The overall reduction in inflammation flaring up (0 episodes amongst the
rheumatoid arthritis group during the trial) appears to be correlated to the
pain reduction (72% of participant experienced a significant reduction in pain
during the trial). This reduction in pain coincides with greater appetite (52%
increase) (correlated to reduced pain) and easier movement (increased by
53%) (correlated to reduced inflammation). The treatment was found to be less
effective (39%) in reducing fatigue and less effective (27%) in improving sleep
quality.
Biography
Anat Avissar Koren, 36 years old, one of the lucky people
with Multiple Sclerosis. My first MS attack happened mid-
pregnancy with my daughter Ruth, and put me in a wheelchair.
Upon recovering I started looking for a way to walk again.
A wheelchair was unacceptable to me. There was nothing I
wouldn't do for my baby Ruth. I was looking for information and
medicine reviews online and at local communities, but found
none. There was no one to explain to me which vitamins will I
benefit from, what supplements and life factors are influential
alongside the treatment, etc. I started studying and soon came
up with the idea for a combo to prevent further attacks. To my
surprise, after 2-3 months of trying, it worked. Later, the combo
was tried by 1,349 more people in Europe for 3 months with
amazing reported results.
founder@lifeaidcombo.comLifeAid Combo trial: rheumatoid arthritis
Avissar Koren A
1
and Styr B
2
1
Acc Triza Granot Ltd, Israel
2
The Hebrew University of Jerusalem, Israel
Avissar Koren et al., J Clin Exp Orthop 2018, Volume: 4
DOI: 10.4172/2471-8416-C1-005